Literature DB >> 33692500

Benefit of nectin-4 targeting with enfortumab vedotin confirmed.

Diana Romero1.   

Abstract

Entities:  

Year:  2021        PMID: 33692500     DOI: 10.1038/s41585-021-00449-1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

  1 in total
  1 in total

Review 1.  Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Authors:  Hiroki Hashimoto; Yuka Tanaka; Maho Murata; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.